Media ReleasesNext Science

View All Next Science News

Next Science - Half Year Results

Next Science Limited (ASX:NXS) (Next Science) today announces its Half Year Report for the six months ended 30 June 2021.


- 1H Revenue US$3.9M (271% growth on prior half year)
- Gross Profit increased 234% on prior half year
- EBIT improved 38% on prior half year
- Cash on hand US$13.2M
- XPerienceTM No Rinse Antimicrobial Solution 510(k) process cleared by the FDA & VAC submissions commenced
- BlastXTM sales returned to Next Science & sales growing
- TGA Approval for BlastX in Australia

Key Activities

Next Science researches, develops and commercialises products which are based on its proprietary XbioTM technology to resolve the issues caused by biofilms and their incumbent bacteria, fungi and viruses and the infections they cause in relation to human health. Next Science commercialises its technologies through a range of methods including licensing, product distribution partnerships, direct sales and product distribution via a network of independent sales representatives.

Managing Director, Judith Mitchell, commented: “Our 1H2021 results have been a record for Next Science in our short history. We are pleased with the current trajectory of the business and look forward to reporting the further success of our products in the marketplace, boosted by the addition of XPerience to our product offering.

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.